HILS
Tharimmune, Inc. is a biotechnology company based in the U.S. focused on developing innovative therapeutics for rare immune, inflammatory, and oncologic diseases. The company is working on treating chronic pruritis related to primary biliary cholangitis and has an early-stage pipeline of immuno-oncology candidates, utilizing unique multi-specific antibodies. Tharimmune has partnered with OmniAb, Inc. for antibody discovery technology to enhance its research capabilities.